

### WHY COLLABORATE WITH CSL?



**Global** capabilities on your doorstep.



**Work** with one of the world's leading biotech companies.



**Funding** for successful proposals.



**Access** to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise.



Accelerate translation of your research to deliver new therapies to patients.

# **CSL Research Acceleration Initiative**

## Seeking Expressions of Interest from Research Organisations

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives.

CSL's **Research Acceleration Initiative** aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations. These partnerships provide funding and access to industry experts for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas.

**Expressions of interest** are sought from Business Development / Commercialisation representatives across global research organisations that wish to participate in the 2022 CSL Research Acceleration Initiative.

The 2022 Research Acceleration Initiative will focus on innovative research projects that address unmet medical needs and are aligned with CSL's **Therapeutic Areas** and scientific **Platforms**:



### **CSL Research Acceleration Initiative**

### Additional Information

### REGISTER YOUR RESEARCH ORGANISATION

BD / Commercialisation representatives from research organisations (universities, medical research institutes, hospitals) are invited to register their organisation's interest to participate in the 2022 Research Acceleration Initiative by emailing RAI@csl.com.au by 10 December 2021 expressing your interest to participate.

#### ASSIGN YOUR PRIMARY CONTACT

CSL requests that each research organisation nominate **one** BD / Commercialisation representative to be assigned as the primary contact for CSL.

#### CALLS FOR SCIENTIFIC PROPOSALS

CSL will work with nominated BD / Commercialisation representatives from participating research organisations to seek scientific proposals that align with the focus areas for the 2022 Research Acceleration Initiative. Focus areas will be available for registered organisations in December. Scientists who wish to apply will be asked to submit a 300-word online abstract that outlines their proposal. Online submission of abstracts will open in January 2022.



### LIMITATIONS ON SUBMISSIONS

There is no limit on the number of abstracts that can be submitted by registered research organisations.

### **FUNDING**

Successful applicants will receive up to \$250,000 AUD per year for up to two years (maximum \$500,000 AUD funding) to accelerate translation of their research. Funding is subject to successful negotiation and execution of a research collaboration agreement between CSL and research organisation.











Plasma Fractionation

Recombinant Technology Cell and Gene Therapy